Day: August 22, 2022

PHOENIX, Aug. 22, 2022 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini Holdings” or the “Company”) (Nasdaq: WSC), the North American leader in innovative flexible workspace and portable storage solutions, today announced a definitive agreement, whereby the Company will divest its Tank and Pump segment to private equity firm Kinderhook Industries (“Kinderhook”) for an enterprise value of approximately $323 million, subject to customary post-closing adjustments. Proceeds from the sale will be used to support ongoing reinvestment in the Company’s core Modular and Storage operating segments and other capital allocation priorities. The transaction is subject to customary closing conditions and regulatory approval and is expected to close in the third quarter of 2022. Eric John, Senior Vice President of the Tank and Pump segment, will serve as the Chief Executive Officer of the newly independent business.

Brad Soultz, Chief Executive Officer of WillScot Mobile Mini Holdings, commented, “Today’s announcement is aligned with our long-term strategy of optimizing our core Modular and Storage segments and staying laser-focused on the growth levers that we articulated at our November 2021 Investor Day. Consistent with our capital allocation framework, we expect to redeploy the proceeds from this transaction to compound growth and returns in our core segments through organic reinvestment, continued tuck-in acquisitions, repurchases of our Common Stock, and de-leveraging within our target range. As most recently evident in our second quarter earnings, the opportunities to reinvest in our core Modular and Storage segments are abundant and attractive, and we can pursue them even more effectively by further concentrating our human and financial capital. We expect to update our financial guidance upon closing of the transaction and anticipate any impact to our third quarter of 2022 operating results to be minimal. I want to thank Eric and the entire team for their hard work and dedication to WillScot Mobile Mini and expect they will flourish as an independent company.”

Eric John, Chief Executive Officer of Tank and Pump, said, “This is a new and exciting journey for our entire team. We look forward to partnering with Kinderhook, which has deep experience helping industry leading middle market businesses navigate their next chapter of growth. Through our partnership and as a standalone business, we will have dedicated leadership and financial capital to build upon our industry-leading customer value proposition and accelerate investments in growth with greater financial and operational flexibility. We are incredibly excited for the Tank & Pump organization and the future of our business.”

BofA Securities acted as the financial adviser and Allen & Overy acted as legal adviser to WillScot Mobile Mini Holdings.

Forward-Looking Statements
This press release contains forward-looking statements (including the guidance/outlook contained herein) within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “estimates,” “expects,” “anticipates,” “believes,” “forecasts,” “plans,” “intends,” “may,” “will,” “should,” “shall,” “outlook” and variations of these words and similar expressions identify forward-looking statements, which are generally not historical in nature. Certain of these forward-looking statements include statements relating to: robust demand continuing, our ability to continue acceleration of commercial momentum, our pipeline, further acceleration of our run rate, the timing of our achievement of our three to five year milestones, our ability to grow predictable reoccurring revenue streams, compound cash generation, drive higher returns on invested capital, and Adjusted EBITDA margin expansion. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other important factors, many of which are outside our control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Although the Company believes that these forward-looking statements are based on reasonable assumptions, they are predictions and we can give no assurance that any such forward-looking statement will materialize. Important factors that may affect actual results or outcomes include, among others, our ability to acquire and integrate new assets and operations; our ability to achieve planned synergies related to acquisitions; our ability to manage growth and execute our business plan; our estimates of the size of the markets for our products; the rate and degree of market acceptance of our products; the success of other competing modular space and portable storage solutions that exist or may become available; rising costs adversely affecting our profitability; potential litigation involving our Company; general economic and market conditions impacting demand for our products and services; our ability to maintain an effective system of internal controls; and such other risks and uncertainties described in the periodic reports we file with the SEC from time to time (including our Form 10-K for the year ended December 31, 2021), which are available through the SEC’s EDGAR system at www.sec.gov and on our website. Any forward-looking statement speaks only at the date which it is made, and the Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About WillScot Mobile Mini Holdings Corp.

WillScot Mobile Mini Holdings trades on the Nasdaq stock exchange under the ticker symbol “WSC.” Headquartered in Phoenix, Arizona, the Company is a leading business services provider specializing in innovative flexible mobile office, portable storage and workspace productivity solutions. WillScot Mobile Mini services diverse end markets across all sectors of the economy from a network of over 275 branch locations and additional drop lots throughout the United States, Canada, Mexico, and the United Kingdom.

Media Contact Information

Jessica Taylor

jetaylor@willscotmobilemini.com

Investor Contact Information

Nick Girardi

nick.girardi@willscotmobilemini.com

Integrating the Collection & Review and Investigative Analytics functions resolves cases faster and accelerates time to justice

PETAH TIKVA, Israel and TYSONS CORNER, Va., Aug. 22, 2022 (GLOBE NEWSWIRE) — Cellebrite DI Ltd. (NASDAQ: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, today announced the launch of an automated and secure system that enables investigative analytics stakeholders to collect, review, and analyze data in an integrated workflow.

By providing a secure and frictionless process, Cellebrite is breaking down silos and accelerating the analysis of evidence. The streamlined process gives enriched data to examiners, analysts, and prosecutors to execute their respective roles.

With a more efficient workflow, Cellebrite is eliminating pain points by empowering agencies to provide data to the analysis team rapidly with secure storage and decoding, delivering a richer investigative data set.

Cellebrite is improving scalability, accountability, and auditability compared to previous methods.

Ori Nurick, Executive Vice President of Portfolio Strategy at Cellebrite, stated: “Every second counts in complex examinations that require access to data, and the conversion of retrieved data into a readable format eases the process on law enforcement. By streamlining the transfer of data to the investigative team, we are providing our customers the tools to shave hours off their workflows and bring evidence to prosecutors faster.”

About Cellebrite

Cellebrite’s (NASDAQ: CLBT) mission is to enable its customers to protect and save lives, accelerate justice, and preserve privacy in communities around the world. We are a global leader in Digital Intelligence solutions for the public and private sectors, empowering organizations in mastering the complexities of legally sanctioned digital investigations by streamlining intelligence processes. Trusted by thousands of leading agencies and companies worldwide, Cellebrite’s Digital Intelligence platform and solutions transform how customers collect, review, analyze and manage data in legally sanctioned investigations. To learn more visit us at www.cellebrite.com, https://investors.cellebrite.com, or follow us on Twitter at @Cellebrite.

Cellebrite Media
Victor Cooper
Public Relations and Corporate Communications Director
+1 404.804.5910
victor.cooper@cellebrite.com

SAN DIEGO and BASEL, Switzerland, Aug. 22, 2022 (GLOBE NEWSWIRE) — Bright Peak Therapeutics, a biotechnology company developing next-generation precision immunotherapies to treat cancer and autoimmune disease, today announced the appointment of Jon Wigginton, M.D., as its President of Research and Development.

“With a lifelong dedication to improving the lives of patients with cancer, Dr. Wigginton is an internationally recognized expert in immunotherapy drug development. Jon helped demonstrate initial therapeutic synergy and key mechanisms of action of several cytokine-based regimens including IL-2 and IL-18 and oversaw the early clinical development of the BMS Immuno-Oncology portfolio. Jon’s exceptional track record in basic science, translational research, and clinical development will be incredibly valuable to our organization as we advance the development of our portfolio of novel precision immunotherapies,” said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. “On behalf of the entire company and Board of Directors, I would like to welcome Jon to the team.”

Dr. Wigginton has over 25 years of experience in clinical oncology and most recently served as Senior Advisor and Chairman of the Scientific Advisory Board at Cullinan Oncology, Inc., having previously served as the company’s Chief Medical Officer. Prior, he was Chief Medical Officer at MacroGenics, where he led the company’s evolution of a fully-integrated clinical-stage cancer immunotherapy organization. Dr. Wigginton also held leadership positions at Bristol Myers Squibb as Therapeutic Area Head and Executive Director, Immuno-Oncology Early Clinical Research and as Group Medical Director of Discovery Medicine-Clinical Oncology. There, he led early clinical development of the BMS Immuno-Oncology portfolio, including checkpoint inhibitors such as anti-PD-1 (Nivolumab)/Opdivo^®) and anti-PD-L1 (BMS-936559), checkpoint inhibitor-based combinations including anti-CTLA-4 (Yervoy^®)/anti-PD-1 (Opdivo^®) among others, and a spectrum of other I-O agents. He also co-founded and co-led the BMS International Immuno-Oncology Network (IION). Dr. Wigginton also previously served as President of the Society for Immunotherapy of Cancer (SITC). Earlier in his career, Dr. Wigginton worked at the National Cancer Institute for 15 years, and served as Head of the Investigational Biologics Section in the Center for Cancer Research (NCI intramural program). There, he demonstrated the initial therapeutic synergy and key mechanisms of action by several novel cytokine-based regimens including IL-2 in combination with IL-18, as well as IL-12 and IL-27 among others. Dr. Wigginton is currently a member of the Board of Directors of Sutro Biopharma. He earned his M.D. and B.S in biology from the University of Michigan.

“Bright Peak is advancing a unique portfolio of first-in-class, cytokine-based precision immunotherapies which have demonstrated compelling selectivity, and safety/efficacy profiles in preclinical models. I look forward to joining Fred and the talented team at Bright Peak, and the opportunity to lead the advancement of these promising, next-generation investigational cytokines for patients with cancer and autoimmune disease,” said Dr. Wigginton.

About Bright Peak Therapeutics
Bright Peak is a privately held biotechnology company based in Basel, Switzerland and San Diego, CA. We use our unique ability to chemically synthesize and conjugate proteins to create a novel portfolio of designer immunotherapies for the treatment of cancer and autoimmune diseases. Our pipeline stretches from discovery to IND-enabling and encompasses enhanced cytokines, antibody-cytokine conjugates and other novel formats. Bright Peak is funded by a syndicate of leading healthcare investors.

Contact:
info@brightpeaktx.com